Finanzas de Connect Biopharma Holdings Ltd (CNTB)CNTBConnect Biopharma Holdings Ltd

Evaluating the bottom line, Connect Biopharma Holdings Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -635.98%, while the net margin is -624.42%. These profitability ratios, combined with a Return on Equity (ROE) of -140.51%, provide a clear picture of how effectively CNTB converts its operational activities into shareholder value.

In the context of the broader market, CNTB competes directly with industry leaders such as HYPD and CTOR. With a market capitalization of $45.68M, it holds a significant position in the sector. When comparing efficiency, CNTB's gross margin of 100.00% stands against HYPD's 100.00% and CTOR's 67.07%. Such benchmarking helps identify whether Connect Biopharma Holdings Ltd is trading at a premium or discount relative to its financial performance.

Connect Biopharma's financial performance is concerning, with a net income loss of $17,284,000 in the most recent quarter and a year-to-date change of -69.16%. The company has shown inconsistent revenue generation, with total revenue of only $2,768,000 in Q2 2026 compared to a significant loss.